Literature DB >> 8016418

Criteria for diagnosis of Sjögren's syndrome.

R I Fox1, I Saito.   

Abstract

The criteria for diagnosis of SS remain controversial, and several sets of diagnostic criteria have been proposed. On one hand, we have used a stringent set of criteria (termed the San Diego criteria) that requires evidence for an autoimmune process associated with destruction of salivary and lacrimal gland tissues. At the other extreme, several groups (including the Copenhagen and EEC Study group) have based their diagnostic criteria on clinical findings of dry eyes and mouth with no absolute requirement for gland biopsy or presence of autoantibodies. The EEC study group believe that the San Diego criteria identify only the tip of the iceberg--namely, those patients with full-blown disease--and ignore those patients with milder forms of SS. Until the underlying pathogenesis of SS is known, we suggest the continued use of the San Diego criteria for classification of SS, because it identifies a group of patients with serologic and histologic evidence for a systemic autoimmune process in association with their sicca symptoms. In patients lacking such evidence for an autoimmune process, we suggest the classification "sicca syndrome" or "dry mouth syndrome." This will allow the clinicians and clinical trials to focus on a more homogeneous group of SS patients who may share a common pathogenesis, treatment response, and prognosis. Also, patients lacking evidence of an autoimmune role in pathogenesis can be reassured, and other causes for their sicca symptoms can be investigated. Further, in the United States the particular diagnosis codes may have implications in obtaining insurance and other medical benefits. Thus, classification criteria involve not only future epidemiologic studies but also economic considerations for the individuals who are given a particular diagnostic code.

Entities:  

Mesh:

Year:  1994        PMID: 8016418

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  27 in total

1.  Possible involvement of IL-12 expression by Epstein-Barr virus in Sjögren syndrome.

Authors:  M Horiuchi; S Yamano; H Inoue; J Ishii; Y Nagata; H Adachi; M Ono; J N Renard; F Mizuno; Y Hayashi; I Saito
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

2.  Association of systemic and thyroid autoimmune diseases.

Authors:  Edit Biró; Zoltán Szekanecz; László Czirják; Katalin Dankó; Emese Kiss; Nóra Anna Szabó; Gabriella Szucs; Margit Zeher; Edit Bodolay; Gyula Szegedi; Gyula Bakó
Journal:  Clin Rheumatol       Date:  2005-10-25       Impact factor: 2.980

3.  Efficacy prediction of cevimeline in patients with Sjögren's syndrome.

Authors:  Hiroyuki Yamada; Yoichi Nakagawa; Ei Wakamatsu; Takayuki Sumida; Shigeo Yamachika; Yoshiaki Nomura; Kenji Mishima; Ichiro Saito
Journal:  Clin Rheumatol       Date:  2007-01-13       Impact factor: 2.980

4.  Immunohistological analysis of tumour growth factor beta 1 expression in normal and inflamed salivary glands.

Authors:  Y Kizu; H Sakurai; S Katagiri; N Shinozaki; M Ono; K Tsubota; J Saito
Journal:  J Clin Pathol       Date:  1996-09       Impact factor: 3.411

Review 5.  Vth International Symposium on Sjögren's syndrome. Clinical aspects and therapy.

Authors:  R I Fox
Journal:  Clin Rheumatol       Date:  1995-07       Impact factor: 2.980

6.  New treatment of dry eye: the effect of calcium ointment through eyelid skin delivery.

Authors:  K Tsubota; Y Monden; Y Yagi; E Goto; S Shimmura
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

7.  Interleukin-10 up-regulates tumour-necrosis-factor-alpha-related apoptosis-inducing ligand (TRAIL) gene expression in mammary epithelial cells at the involution stage.

Authors:  B H Sohn; H B Moon; T Y Kim; H S Kang; Y S Bae; K K Lee; S J Kim
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

8.  Treatment of dry eye by autologous serum application in Sjögren's syndrome.

Authors:  K Tsubota; E Goto; H Fujita; M Ono; H Inoue; I Saito; S Shimmura
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

9.  Albumin as a tear supplement in the treatment of severe dry eye.

Authors:  S Shimmura; R Ueno; Y Matsumoto; E Goto; A Higuchi; J Shimazaki; K Tsubota
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

Review 10.  Myelopathy in Sjögren's syndrome: role of nonsteroidal immunosuppressants.

Authors:  Susan J Rogers; Christopher S Williams; Gustavo C Román
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.